Payment overview · 2025
General Payments
$35.15
2 reported records · 2 companies
Healthcare provider profile · identity verified
Yanet Perez Prieto
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MIAMI, FL · NPI 1306296603
Verified facts
What the public records show
CMS Open Payments records show Yanet Perez Prieto received $35.15 in general payments during 2025 across 2 reported records.
Sumitomo Pharma America, Inc. accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.00 | 51.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.15 | 48.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $35.15 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 264 |
| Gabapentin | Gabapentin | 541 | 163 |
| Lisinopril | Lisinopril | 396 | 119 |
| Montelukast Sodium | Montelukast Sodium | 375 | 111 |
| Metformin Hcl | Metformin Hcl | 372 | 127 |
| Losartan Potassium | Losartan Potassium | 356 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 104 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 321 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 84 |
| Fluticasone Propionate | Fluticasone Propionate | 312 | 78 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 302 | 109 |
| Omeprazole | Omeprazole | 279 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 64 |
| Ibuprofen | Ibuprofen | 214 | 80 |
| Folic Acid | Folic Acid | 204 | 65 |
| Simvastatin | Simvastatin | 200 | 64 |
| Glipizide | Glipizide | 180 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 170 | 24 |
| Memantine Hcl | Memantine Hcl | 149 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 41 |
| Eliquis | Apixaban | 137 | 28 |
| Famotidine | Famotidine | 135 | 40 |
| Alendronate Sodium | Alendronate Sodium | 130 | 37 |
| Furosemide | Furosemide | 109 | 40 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 106 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 29 |
| Ammonium Lactate | Ammonium Lactate | 95 | 31 |
| Jardiance | Empagliflozin | 93 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 35 |
| Januvia | Sitagliptin Phosphate | 87 | 18 |
| Atenolol | Atenolol | 80 | 24 |
| Farxiga | Dapagliflozin Propanediol | 80 | 14 |
| Allopurinol | Allopurinol | 75 | 22 |
| Latanoprost | Latanoprost | 75 | 12 |
| Meclizine Hcl | Meclizine Hcl | 74 | 38 |
| Carvedilol | Carvedilol | 73 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 71 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 71 | 18 |
| Baclofen | Baclofen | 66 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 22 |
| Ketoconazole | Ketoconazole | 62 | 25 |
| Donepezil Hcl | Donepezil Hcl | 61 | 26 |
| Meloxicam | Meloxicam | 61 | 32 |
| Azithromycin | Azithromycin | 60 | 56 |
| Enalapril Maleate | Enalapril Maleate | 59 | 15 |
| Ozempic | Semaglutide | 58 | 15 |
| Nifedipine Er | Nifedipine | 55 | 18 |
| Tadalafil | Tadalafil | 55 | 12 |
| Novolog Flexpen | Insulin Aspart | 54 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 22 |
| Cilostazol | Cilostazol | 51 | 15 |
| Brilinta | Ticagrelor | 49 | suppressed |
| Nystatin | Nystatin | 47 | 15 |
| Lactulose | Lactulose | 46 | 14 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 39 |
| Ezetimibe | Ezetimibe | 44 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 13 |
| Bumetanide | Bumetanide | 42 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | 16 |
| Metronidazole | Metronidazole | 42 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Gemfibrozil | Gemfibrozil | 40 | 11 |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 39 | 22 |
| Mupirocin | Mupirocin | 38 | 23 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | 11 |
| Fenofibrate | Fenofibrate | 37 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 13 |
| Ciclopirox | Ciclopirox | 33 | 11 |
| Glimepiride | Glimepiride | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 30 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 17 |
| Irbesartan | Irbesartan | 29 | 11 |
| Naproxen | Naproxen | 29 | 16 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Pentoxifylline | Pentoxifylline | 28 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 27 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | 14 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 11 |
| Spironolactone | Spironolactone | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | 13 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | 12 |
| Dorzolamide Hcl | Dorzolamide Hcl | 17 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 13 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35.15 · 2 records | Sumitomo Pharma America, Inc. | ABILIFY ASIMTUFII, GEMTESA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error